Key Highlights
- Shares of ARS Pharmaceuticals (NASDAQ:SPRY) were quoted at USD 3.41 on Thursday, November 19, 2026, down 7.62% in intraday market data, which points to a prior close near USD 3.69 (calculated).
- Quarterly Revenue of USD 37.7 million for the third quarter outpaced USD 32.5 million a year before, with U.S. net product sales of neffy at USD 33.4 million, up from USD 31.3 million.
- The loss contracted to USD 35.6 million, which is USD 0.36 per share, down from USD 51.2 million or USD 0.52, as selling outlays fell from USD 74.8 million to USD 43.5 million.
- Cash and short-term investments totalled USD 138.4 million on September 30, 2026, versus roughly USD 245.0 million on December 31, 2025, and the company targets Cash Flow breakeven at year-end 2027.
No Corporate Trigger Surfaces Behind the Share Pullback
ARS Pharmaceuticals (NASDAQ:SPRY) traded lower by 7.62% to USD 3.41 on November 19, 2026. Searches of company releases and filings dated November 17 through 19 produced no announcement, and no analyst action appeared either, so the decline cannot be pinned on a specific event. The latest substantive news is the third-quarter release from November 5, 2026. The firm sells neffy, a needle-free epinephrine nasal spray intended for serious allergic reactions such as anaphylaxis, and the product is still early in its commercial rollout. Small, low-priced healthcare stocks often slip on light Volume or profit-taking alone, which means this session tells investors little about underlying sales.
Neffy Sales Advance, but Not as Fast as Prescriber Interest
Revenue from neffy in the United States moved from USD 31.3 million to USD 33.4 million, a calculated rise of about 6.7%. Management said end-user Demand grew more quickly and linked the difference to swings in wholesale channel inventory. Other revenue streams contributed USD 2.6 million from Supply and USD 1.7 million from collaborations. A single published report said commercial coverage slipped above 80% of covered lives and that revenue fell below market expectations. Overhead for selling and admin shrank after linear TV and mass consumer ads were dropped, whereas R&D spending reached USD 18.3 million, lifted by a single USD 12.5 million license outlay.
Runway Math, Term Loan Figures and the ARS-2 Milestone
Cash on hand comprised USD 25.6 million of cash plus USD 112.7 million of short-term investments, a combined USD 138.4 million. For the second half of 2026, the company expects selling, administrative and research outlays between USD 114 million and USD 126 million, with Stock Compensation included. Published coverage put the term loan near USD 121.8 million, a number not confirmed in this review. A count of 100,248,400 shares outstanding was reported as of September 30, 2026. An interim readout from the ARS-2 Phase 2b program in chronic spontaneous urticaria lands in the first quarter of 2027, and falling short of the breakeven aim would push up financing odds.
Where Things Stand
The 7.62% fall has no announced corporate cause. ARS Pharmaceuticals (NASDAQ:SPRY) last reported on November 5, 2026, with revenue growth and a narrower loss, but neffy sales trailed demand and cash dropped about USD 107 million since December 31, 2025 (calculated). A share priced under USD 5 can swing on a handful of trades, and quoted moves may reverse. Watch fourth-quarter neffy revenue, insurance coverage progress, the spending range and the ARS-2 readout in early 2027.






Please wait processing your request...